{"id":3260,"count":141,"description":"The MedsBase Heart & Blood Pressure parent catalogue groups all cardiovascular medications \u2014 antihypertensives across the major drug classes, anti-anginal nitrates, anti-arrhythmics, heart-failure agents, and pulmonary arterial hypertension specialty drugs. The detailed clinical breakdown by drug class with full molecule and brand listing is in our \u041b\u0435\u043a\u0430\u0440\u0441\u0442\u0432\u0430 \u0437\u0430 \u0432\u0438\u0441\u043e\u043a\u043e \u043a\u0440\u044a\u0432\u043d\u043e \u043d\u0430\u043b\u044f\u0433\u0430\u043d\u0435<\/a> \u043f\u043e\u0434\u043a\u0430\u0442\u0435\u0433\u043e\u0440\u0438\u044f \u2014 \u043c\u043e\u043b\u044f, \u0440\u0430\u0437\u0433\u043b\u0435\u0434\u0430\u0439\u0442\u0435 \u0442\u0430\u043c \u0437\u0430 \u043d\u0430\u0441\u043e\u043a\u0438 \u0437\u0430 \u0438\u0437\u0431\u043e\u0440 \u0438 \u043a\u043e\u043d\u0442\u0435\u043a\u0441\u0442 \u043d\u0430 \u0434\u043e\u0437\u0438\u0440\u0430\u043d\u0435\u0442\u043e. \u0412\u0441\u0438\u0447\u043a\u0438 \u043f\u0440\u043e\u0434\u0443\u043a\u0442\u0438 \u0441\u0435 \u0434\u043e\u0441\u0442\u0430\u0432\u044f\u0442 \u043e\u0442 WHO-GMP \u0441\u0435\u0440\u0442\u0438\u0444\u0438\u0446\u0438\u0440\u0430\u043d\u0438 \u043f\u0440\u043e\u0438\u0437\u0432\u043e\u0434\u0438\u0442\u0435\u043b\u0438<\/strong>.\n\n\u0420\u0435\u0437\u044e\u043c\u0435 \u043d\u0430 \u043a\u043b\u0430\u0441\u043e\u0432\u0435 \u043b\u0435\u043a\u0430\u0440\u0441\u0442\u0432\u0430.<\/strong> ARBs (angiotensin-receptor blockers \u2014 losartan, valsartan, telmisartan, olmesartan, candesartan, irbesartan), ACE inhibitors (ramipril, lisinopril, enalapril, perindopril, captopril), beta-blockers (atenolol, metoprolol, bisoprolol, carvedilol, nebivolol, propranolol, labetalol, esmolol), calcium-channel blockers (amlodipine, nifedipine, felodipine, diltiazem, verapamil), diuretics (hydrochlorothiazide, indapamide, furosemide, torasemide, bumetanide, spironolactone, eplerenone, amiloride), alpha-blockers (prazosin, terazosin, doxazosin), centrally-acting agents (clonidine, alpha-methyldopa), nitrates (isosorbide mononitrate, isosorbide dinitrate, nitroglycerin sublingual \/ spray \/ patch), and specialty agents (ivabradine for HF, ambrisentan and riociguat for PAH, minoxidil for resistant HTN, sacubitril-valsartan for HFrEF).\n\nAnti-thrombotic adjuncts.<\/strong> Aspirin 75\u2013325 mg (Ecosprin), clopidogrel (Clodict, Plavix), warfarin (Warf, Waf-5), DOACs (Xarelto rivaroxaban, Eliquis apixaban) for primary and secondary cardiovascular prevention. See our \u0410\u043d\u0442\u0438\u043a\u043e\u0430\u0433\u0443\u043b\u0430\u043d\u0442\u0438<\/a> \u043a\u0430\u0442\u0435\u0433\u043e\u0440\u0438\u044f.\n\nLipid-lowering co-treatment.<\/strong> Statins (atorvastatin, rosuvastatin, simvastatin, pitavastatin), fenofibrate, ezetimibe, and cholestyramine for cardiovascular risk reduction \u2014 see our \u041b\u0435\u0447\u0435\u043d\u0438\u0435 \u043d\u0430 \u0432\u0438\u0441\u043e\u043a \u0445\u043e\u043b\u0435\u0441\u0442\u0435\u0440\u043e\u043b<\/a> \u043a\u0430\u0442\u0435\u0433\u043e\u0440\u0438\u044f.\n\n\u041a\u0430\u043a \u0434\u0430 \u0438\u0437\u0431\u0435\u0440\u0435\u0442\u0435.<\/strong> Modern ESC \/ NICE 2023 first-line for hypertension: ARB or ACE inhibitor (under 55, non-Black) OR calcium-channel blocker (over 55 or Black). Step-up to dual therapy (ARB\/ACEi + CCB), then triple (add thiazide \/ thiazide-like diuretic), then quadruple (add spironolactone if K+ < 4.5). Target BP < 140\/90 (130\/80 in diabetes \/ CKD \/ high CVD risk). Heart-failure with reduced ejection fraction (HFrEF) \u2014 sacubitril-valsartan (or ARB\/ACEi) + beta-blocker + MRA + SGLT-2 inhibitor (the four pillars). Coronary artery disease \u2014 beta-blocker + statin + antiplatelet + ACEi\/ARB if HTN or LV dysfunction.\n\n\u0412\u0430\u0436\u043d\u043e.<\/strong> Cardiovascular medications work best when taken consistently \u2014 please keep your primary-care team and cardiologist informed. Sudden discontinuation of beta-blockers or clonidine causes rebound hypertension \/ angina \/ arrhythmia \u2014 always taper. ACEi \/ ARB combinations are no longer recommended (ON-TARGET trial). Pregnancy: ACE inhibitors and ARBs are absolutely contraindicated; methyldopa, labetalol, nifedipine are first-line for pregnancy hypertension. Severe symptomatic hypotension, syncope, oedema, breathlessness, palpitations, or chest pain warrants prompt medical assessment.\n\nAll MedsBase Heart & Blood Pressure products ship from WHO-GMP \u0441\u0435\u0440\u0442\u0438\u0444\u0438\u0446\u0438\u0440\u0430\u043d\u0438 \u043f\u0440\u043e\u0438\u0437\u0432\u043e\u0434\u0438\u0442\u0435\u043b\u0438<\/strong> \u0441 \u0434\u0438\u0441\u043a\u0440\u0435\u0442\u043d\u0430 \u043e\u043f\u0430\u043a\u043e\u0432\u043a\u0430 \u0438 \u0441\u0430 \u043f\u043e\u043a\u0440\u0438\u0442\u0438 \u043e\u0442 \u043d\u0430\u0448\u0430\u0442\u0430 \u041f\u043e\u043b\u0438\u0442\u0438\u043a\u0430 \u0437\u0430 \u043f\u043e\u0432\u0442\u043e\u0440\u043d\u0430 \u0438\u0437\u043f\u0440\u0430\u0442\u043a\u0430<\/a>.","link":"https:\/\/medsbase.com\/bg\/heart-blood-pressure\/","name":"\u0421\u044a\u0440\u0446\u0435 \u0438 \u043a\u0440\u044a\u0432\u043d\u043e \u043d\u0430\u043b\u044f\u0433\u0430\u043d\u0435","slug":"heart-blood-pressure","taxonomy":"product_cat","parent":3223,"meta":[],"menu_order":0,"acf":[],"_links":{"self":[{"href":"https:\/\/medsbase.com\/bg\/wp-json\/wp\/v2\/product_cat\/3260","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/medsbase.com\/bg\/wp-json\/wp\/v2\/product_cat"}],"about":[{"href":"https:\/\/medsbase.com\/bg\/wp-json\/wp\/v2\/taxonomies\/product_cat"}],"up":[{"embeddable":true,"href":"https:\/\/medsbase.com\/bg\/wp-json\/wp\/v2\/product_cat\/3223"}],"wp:post_type":[{"href":"https:\/\/medsbase.com\/bg\/wp-json\/wp\/v2\/product?product_cat=3260"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}